Inovio Pharmaceuticals Stock Performance
| INO Stock | USD 1.92 0.02 1.03% |
Inovio Pharmaceuticals has a performance score of 3 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 1.37, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Inovio Pharmaceuticals will likely underperform. Inovio Pharmaceuticals right now retains a risk of 4.7%. Please check out Inovio Pharmaceuticals skewness, as well as the relationship between the day median price and relative strength index , to decide if Inovio Pharmaceuticals will be following its current trending patterns.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Inovio Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Inovio Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
Last Split Factor 1:12 | Last Split Date 2024-01-25 |
1 | Whats Going On With Inovio Pharmaceuticals Stock | 01/08/2025 |
2 | Disposition of 35000 shares by Sumner Michael John of Inovio Pharmaceuticals subject to Rule 16b-3 | 01/17/2025 |
3 | Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology Conference | 02/10/2025 |
4 | Inovio respiratory DNA drug candidate shows promise in early trial | 02/12/2025 |
5 | Disposition of 972 shares by Weiner David B. of Inovio Pharmaceuticals subject to Rule 16b-3 | 02/26/2025 |
6 | Acquisition by Peter Kies of 31900 shares of Inovio Pharmaceuticals subject to Rule 16b-3 | 02/27/2025 |
7 | Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20 Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assess... | 03/03/2025 |
8 | Inovio Pharmaceuticals GAAP EPS of -0.65 beats by 0.19, revenue of 0.12M | 03/18/2025 |
9 | Inovio aims for INO-3107 regulatory submission by mid-2025 while addressing key manufacturing issues | 03/19/2025 |
| Begin Period Cash Flow | 14.3 M |
Inovio |
Inovio Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 183.00 in Inovio Pharmaceuticals on December 24, 2024 and sell it today you would earn a total of 9.00 from holding Inovio Pharmaceuticals or generate 4.92% return on investment over 90 days. Inovio Pharmaceuticals is generating 0.1847% of daily returns assuming volatility of 4.7016% on return distribution over 90 days investment horizon. In other words, 41% of stocks are less volatile than Inovio, and above 97% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Inovio Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Inovio Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Inovio Pharmaceuticals, and traders can use it to determine the average amount a Inovio Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0393
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | INO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.7 actual daily | 41 59% of assets are more volatile |
Expected Return
| 0.18 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Inovio Pharmaceuticals is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Inovio Pharmaceuticals by adding it to a well-diversified portfolio.
Inovio Pharmaceuticals Fundamentals Growth
Inovio Stock prices reflect investors' perceptions of the future prospects and financial health of Inovio Pharmaceuticals, and Inovio Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Inovio Stock performance.
| Return On Equity | -1.15 | ||||
| Return On Asset | -0.49 | ||||
| Operating Margin | (174.11) % | ||||
| Current Valuation | (11.85 M) | ||||
| Shares Outstanding | 36.67 M | ||||
| Price To Earning | (5.43) X | ||||
| Price To Book | 1.03 X | ||||
| Price To Sales | 323.30 X | ||||
| Revenue | 217.76 K | ||||
| Gross Profit | (75.4 M) | ||||
| EBITDA | (103.95 M) | ||||
| Net Income | (107.25 B) | ||||
| Cash And Equivalents | 348.13 M | ||||
| Cash Per Share | 1.40 X | ||||
| Total Debt | 11.87 B | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | 1.90 X | ||||
| Cash Flow From Operations | (104.08 B) | ||||
| Earnings Per Share | (3.95) X | ||||
| Market Capitalization | 70.4 M | ||||
| Total Asset | 113.2 B | ||||
| Retained Earnings | (1.73 T) | ||||
| Working Capital | 62.5 M | ||||
| Current Asset | 171.85 M | ||||
| Current Liabilities | 31.47 M | ||||
About Inovio Pharmaceuticals Performance
By examining Inovio Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Inovio Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Inovio Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 184.88 | 196.63 |
Things to note about Inovio Pharmaceuticals performance evaluation
Checking the ongoing alerts about Inovio Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Inovio Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Inovio Pharmaceuticals may become a speculative penny stock | |
| Inovio Pharmaceuticals had very high historical volatility over the last 90 days | |
| Inovio Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 217.76 K. Reported Net Loss for the year was (107.25 B) with loss before taxes, overhead, and interest of (75.4 M). | |
| Inovio Pharmaceuticals has about 348.13 M in cash with (104.08 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.4. | |
| Inovio Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: Inovio aims for INO-3107 regulatory submission by mid-2025 while addressing key manufacturing issues |
- Analyzing Inovio Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Inovio Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Inovio Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Inovio Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Inovio Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Inovio Pharmaceuticals' stock. These opinions can provide insight into Inovio Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.95) | Revenue Per Share | Quarterly Revenue Growth 0.14 | Return On Assets | Return On Equity |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.